EGFR and lung carcinoma: For instance, in EGFR-mutant lung cancer, the addition of LCT has been shown to extend the PFS of EGFR-TKIs treatment from 13.9 months to 20.6 months.13–15 However, the application of LCT for ORD in the setting of immunotherapy remains largely unexplored.